Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Basal Cell Cancer
Research in the area of basal cell cancer reported from Otto-von-Guericke University
February 3rd, 2009
"Imiquimod 5% cream is an immune response modifier approved for the treatment Of superficial basal cell carcinoma (sBCC) once daily, 5 x per week for 6 weeks. This report reveals the final results of 5-year follow-up study to evaluate the recurrence rate of sBCCs treated with imiquimod," scientists in Magdeburg, Germany report. "As previously reported, 182 patients were enrolled in the Study and 163 (89.6%) had no clinical evidence of their target sBCC at the 12-week post-treatment assessment; these 163 were followed for Lip to 5 years. During the follow-up period, 18 clinical recurrences occurred at the target tumour site, 8 and 10 Of Which Occurred during the first 6...
Source: Cancer Weekly (2009-02-03)
|
